Rebecca A. Shatsky, MD, provides an overview of ER+/HER2- metastatic breast cancer and discusses its incidence and prevalence.
Dialogue in Diagnostics: Optimizing ESR1m Testing in ER+/HER2- Metastatic Breast Cancer
A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.
An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.
Rebecca A. Shatsky, MD, reviews biomarker testing guideline recommendations for patients with breast cancer and discusses testing practices upon progression.
A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.
A medical oncologist discusses challenges with conducting molecular testing and reviews clinical trials focused on biomarkers for patients with ER+/HER2- metastatic breast cancer.
Rebecca A. Shatsky, MD, looks to the future of biomarker testing in metastatic breast cancer and offers advice to community oncologists.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
